Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.
Also called NCT01043380
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 245 participants
- Sponsor
- Kumamoto University
- Registry
-
NCT01043380
-
- Other papers using this trial's data
- Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial
- Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial
- Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01043380. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2014-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound
- Acronym
- PRECISE-IVUS
- Condition
- Hypercholesterolemia
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]
- Intervention (Drug)
- Lipitor (Atorvastatin) monotherapy
- Lead sponsor
- Kumamoto University
Record details
- Record id
cardio:ct-nct01043380- Content hash
3565e0e30126a9217e07563cdcbfd71300e7ec47131c7c08ec2bc8da98745b71